A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependence

Alcoholism: Clinical and Experimental Research

Volumn 28, Issue 9, 2004, Pages 1356-1361

  Johnson, Bankole A ^a   Ait Daoud, Nassima ^a   Aubin, Henri Jean ^b   Van Den Brink, Wim ^c   Guzzetta, Richard ^d   Loewy, John ^e   Silverman, Bernard ^e   Ehrich, Elliot ^e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Emile Roux Hospital AP HP   (France)

^c AMSTERDAM INSTITUTE FOR ADDICTION RESEARCH   (Netherlands)

^d Touchstone Medical Group   (United States)

^e ALKERMES INC   (United States)

Author keywords

Alcohol; Humans; Naltrexone; Opioid; Treatment

Indexed keywords

6 BETA NALTREXONE; DRUG METABOLITE; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALCOHOLISM; ANGIONEUROTIC EDEMA; APPETITE DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EVALUATION; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; MULTICENTER STUDY; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VOMITING; XEROSTOMIA;

ADULT; ALCOHOLISM; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG EVALUATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; NALTREXONE; PILOT PROJECTS;

EID: 4544222029     PISSN: 01456008     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ALC.0000139823.30096.52     Document Type: Article

References (22)

1. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of out-patient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156:1758-1764.
2. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al. (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35:587-593.
3. Conigrave KM, Degenhardt LJ, Whitfield JB, Saunders JB, Helander A, Tabakoff B (2002) CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA collaborative project, WHO/ISBRA Study Group. Alcohol Clin Exp Res 26:332-339.
4. Johnson BA, Ait-Daoud N (1999) Medications to treat alcoholism. Alcohol Res Health 23:99-106.
5. Johnson BA, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 149:327-344.
6. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361:1677-1685.
7. Kaempf G, O'Donnell C, Oslin DW (1999) The BRENDA model: a psychosocial addiction model to identify and treat alcohol disorders in elders. Geriatr Nurs 20:302-304.
8. Kiefer F, Jahn H, Tarnaske T, Helwig H, Eriken P, Holzbach R, et al. (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60:92-99.
9. King AC, Volpicelli JR, Gunduz M, O'Brien CP, Kreek MJ (1997) Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 21:906-909.
10. Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22:493-503.
11. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA (2001) Naltrexone in the treatment of alcohol dependence, Veterans Affairs Naltrexone Cooperative Study 425 Group. N Engl J Med 345:1734-1739.
12. O'Brien CP, Volpicelli LA, Volpicelli JR (1996) Naltrexone in the treatment of alcoholism: a clinical review. Alcohol 13:35-39.
13. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49:881-887.
14. O'Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek J (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary- adrenocortical axis. Psychopharmacology 160:19-29.
15. Osborn C, Benziger D, Henderson J, Ehrich E, Mant T, Bartus R (2000) Sustained, 30-day therapeutic levels of naltrexone in a phase I clinical study. Presentation at the American College of Neuropsychopharmacology 39th Annual Meeting, San Juan, Puerto Rico.
16. Pettinati HM, Volpicelli JR, Pierce JD Jr, O'Brien CP (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19:71-83.
17. Skinner HA, Horn JL (1984) Alcohol Dependence Scale: User's Guide. Addiction Research Foundation, Toronto.
18. Sobell LC, Sobell MB (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption, in Measuring Alcohol Consumption: Psychosocial and Biochemical Methods (Litten RZ, Allen JP eds), pp 41-72. Humana Press, Totowa, NJ.
19. Swift RM (1999) Drug therapy for alcohol dependence. N Engl J Med 340:1482-1490.
20. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880.
21. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (2001) Combining Medication and Psychosocial Treatments for Addictions: The BRENDA Approach. Guilford Press, New York.
22. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54:737-742.